study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
LONG-LON03-01,2019,randomized controlled trial,SMD,0.2858,0.1515,0.4201,79,69,mixed,10.1234/long-lon03-01,longevity-journal-01,telomere_support,Adults with telomere support concerns,None reported,11
LONG-LON03-02,2010,randomized controlled trial,SMD,0.2804,0.0937,0.4671,92,84,low,10.1234/long-lon03-02,longevity-journal-02,telomere_support,Adults with telomere support concerns,None reported,10
LONG-LON03-03,2015,randomized controlled trial,SMD,0.275,0.1059,0.4441,75,68,low,10.1234/long-lon03-03,longevity-journal-03,telomere_support,Adults with telomere support concerns,Transient headache,8
